Tech Company Financing Transactions
City Therapeutics Funding Round
Sofinnova Partners, Viking Global Investors and Arch Venture Partners invested in a $99.5 million Series B funding round for City Therapeutics. The funding round was announced by the company on 6/9/2026.
Transaction Overview
Company Name
Announced On
6/9/2026
Transaction Type
Venture Equity
Amount
$99,500,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance its pipeline of RNAi therapeutics, accelerate its new RNAi engineering platform, and support business development activities.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
399 Binney St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Leveraging next-generation trigger molecule engineering, City Therapeutics is building a sustainable product engine of RNAi-based medicines to make a significant impact for patients across multiple therapeutic areas. These include prevalent disease indications where RNAi therapeutics have clear advantages over other modalities such as small molecules and antibodies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
John Maraganore
Chief Operating Officer
Sebastian Trousil
Chief Scientific Officer
Tracy Zimmermann
VP - Bus. Development
Ari Nowacek
Browse more venture capital transactions:
Prev: 6/9/2026: Vinyl Equity venture capital transaction
Next: 6/9/2026: SyntheticFi venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs